Result Filters
Adult attention-deficit/hyperactivity disorder : diagnosis, treatment, and implications for drug development : proceedings of a workshop
- Author(s):
- Babik, Kelsey R, rapporteur
- Shore, Carolyn, rapporteur
- Norris, Sheena M Posey, rapporteur
- Berkower, Carol, rapporteur
- Ontjes, Noah, rapporteur
- National Academies of Sciences Engineering and Medicine (US) Forum on Neuroscience and Nervous System Disorders, issuing body
- National Academies of Sciences Engineering and Medicine (US) Forum on Drug Discovery Development and Translation, issuing body
- Adult Attention-Deficit/Hyperactivity Disorder Diagnosis Treatment and Implications for Drug Development (Workshop) (2023 Washington DC)
- Title(s):
- Adult attention-deficit/hyperactivity disorder : diagnosis, treatment, and implications for drug development : proceedings of a workshop / Kelsey R. Babik, Noah Ontjes, Carol Berkower, Sheena M. Posey Norris, and Carolyn Shore, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division.
- Country of Publication:
- United States
- Publisher:
- Washington, DC : National Academies Press, [2024]
- Description:
- 1 online resource (1 PDF file (xx, 149 pages)) : illustration
-
Language:
- English
- ISBN:
- 9780309719162
030971916X
- Electronic Links:
- https://www.ncbi.nlm.nih.gov/books/NBK604279/
- Summary:
- Attention deficit/hyperactivity disorder (ADHD) diagnosis and treatment among adults has increased over the past decade in the U.S. and globally. Evidence suggests adults with ADHD may be more likely to develop a substance use disorder, and there are concerns that nonmedical use of prescription stimulants could lead to misuse, overdose, or toxicity. In December 2023, The National Academies Forum on Drug Discovery, Development, and Translation and Forum on Neuroscience and Nervous System Disorders held a public workshop to examine the diagnosis and treatment of adults with ADHD and explore the challenges and opportunities for the development of new therapeutics. The workshop was supported, in part, through a grant (PAR-23-072) from the Center for Drug Evaluation and Research at the FDA.
- MeSH:
- Attention Deficit Disorder with Hyperactivity/diagnosis*
Attention Deficit Disorder with Hyperactivity/drug therapy*
Central Nervous System Stimulants/adverse effects
Central Nervous System Stimulants/therapeutic use
Drug Development
Prescription Drug Misuse
- Publication Type(s):
- Congress
- Notes:
- Includes bibliographical references.
Issued also in print.
This activity was supported by contracts between the National Academy of Sciences and Acadia Pharmaceuticals; Alzheimer's Association; American Brain Coalition; American Neurological Association; Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Boehringer Ingelheim (Contract No. 755326); BrightFocus Foundation; Burroughs Wellcome Fund (Contract No. 1023129); California Institute for Regenerative Medicine; Cerevel Therapeutics; Cohen Veterans Bioscience; Department of Veteran Affairs (Contract No. 36C24E20C009); Eisai; Eli Lilly and Company; FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Gatsby Charitable Foundation; Harmony Biosciences; Janssen Research & Development, LLC; Johnson & Johnson; Karuna Therapeutics; Lundbeck Research USA, Inc.; Medable Inc.; Merck & Co., Inc. (Contract No. MRLCPO-23-166623); Michael J. Fox Foundation for Parkinson's Research; National Institutes of Health (Contract No. HHSN263201800029I; Task Order Nos. HHSN26300007 and 75N98024F00001): BRAIN Initiative, National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Diseases, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, and National Institute on Drug Abuse, Office of the Director; National Multiple Sclerosis Society; National Science Foundation; New England Journal of Medicine; One Mind; Paul G. Allen Frontiers Group; Sanofi (Contract No. 77646387); Simons Foundation (Contract No. 995152); Takeda (Contract No. A62909); The George & Anne Ryan Institute for Neuroscience at the University of Rhode Island; U.S. Food and Drug Administration (Contract No. 1R13FD007302-01, Contract No. 1R13FD005362-01, and Contract No. 1R13FD008016); Wellcome Trust. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
- NLM ID:
- 9918897700906676 [Electronic Resource]